Innovation Requirements and Progress of Dialysis Water Treatment System

With the development of medicine,people are becoming more and more aware of the quality of medical water supply,such as dial ysis water,dental water,preparation water,operating room water,supply room water.Therefore,People are constantly improving the water treatment system and its standardized,and the demand for dialysis water is also becoming more and more strict.Hemodialysis is an effective means of maintaining the life of renal failure patients,120~180L water will be used for a conventional dialysis treatment,and high flux dialysis will consume more.

Efficacy and Safety of Febuxost at in the Treatment of Chronic Kidney Disease with Hyperuricemia: A Meta- Analysis

Background Febuxostat and allopurinol have different pharmacological mechanisms,the efficacy of febuxostat in chronic kidney disease complicated with hyperuricemia remains controversial.A meta-analysis and systemic review was conducted to investigate the efficacy and safety of febuxostat in CKD populations complicated with hyperuricemia.Methods A comprehensive search was conducted in multiple electronic databases based on the inclusion and exclusion criteria,before December 2016,searching for the published studies,including Chinese and English,relating to the use of febuxostat in CKD populations complicated with hyperuricemia,and manual retrieval of the inclusion literature.Literature evaluation and data extraction were performed by two reviewers,Rev Man 5.3 was used to perform the meta-analysis.Results Seven studies with 482 CKD patients were included in the meta-analysis.We found that febuxostat can significantly slow the decreasing speed of e GFR[RR=4.90,95%CI(1.95,7.84),P=0.001],and reduce serum uric acid[RR=-99.30,95%CI(-172.24,-26.37),P=0.008]levels in CKD patients complicated with hyperuricemia when compairing with control group.There was no significant difference in the levels of systolic blood pressure[RR=-2.19,95%CI(-9.99,5.61),P=0.58],diastolic blood pressure[RR=-2.30,95%CI(-7.33,2.73),P=0.10],low density lipoprotein[RR=-0.47,95%CI(-7.64,6.69),P=0.90]between the two groups.Compared with the control group,the use of febuxostat increase the incidence of adverse reaction[RR=4.73,95%CI(1.04,21.43),P=0.04]in patients.Conclusions Febuxostat can significantly lower serum uric acid level and effectively delay the process of chronic renal failure in CKD patients complicated with hyperuricemic,increases the incidence of adverse reaction,no significant difference in SBP,DBP,LDL,when compared with control group.

Experimental Design and Clinical Observation of Modialysis Apparatus

Objective To evaluate the clinical safety and efficacy of polyethersulfone membrane hollow fiber dialyzer Enttex^(TM)-16LF(E60)in treating patients with end stage renal disease caused by a variety of reasons.Methods This clinical trialwas designed as a randomized,open,two-phase crossover and positive control,non-inferiority study.To evaluate the indicators of blood routine test,serum biochemical indexes,blood gas analysis,vital signsbefore and after hemodialysis,and the adverse events were recorded indetail.Results There was no significant difference in creatinine,urea,creatinine clearance and electrolytes between Enttex TM-16LF dialyzer and control dialyzer before and after hemodialysis,no adverse event associated with the Enttex^(TM)-16LF dialyzer was found during the study.Conclusions The Enttex^(TM)-16LF dialyzeris effective and safe for hemodialysis in patients with end stage renal disease.

Analysis of Performance Stability and Clinical Efficacy of OBERS - 3000 Hemodialysis Machine

Objective To explore the method of safety and efficacy validation of hemodialysis machine,and observe the clinical efficacy of OBERS-3000 multifunctional hemodialysis machine.Methods Randomized,open,two-phase crossover and positive control design,a total of 72 patients from two hospitals were included.OBERS-3000 multifunctional hemodialysis machine was the test machine,and the Fresenius 4008 series hemodialysis machine was as the control machine,indicators of blood routine test,serum electrolytes,liver and kidney function test,blood gas analysis,CRP were compared,body weight before and after hemodialysis,ultrafiltration volume were recorded,urea clearance index,urea reduction ratio were calculated.The XL90 conductivity meter was connected in series in the test machine,to monitor the temperature,conductance,venous pressure and arterial pressure during the dialysis in real time,and the measured value were compared with the machine monitoring value.Results Both of the test machine and the control machine could effectively eliminate creatinine,urea nitrogen and other uremic toxins,could continuously supply qualified dialysate,and precisely control the ultrafiltration volume.There were no significant differences in temperature,conductance,venous pressure and arterial pressure monitoring with the real time measured value by XL90 conductivity meter.Conclusions OBERS-3000 multifunctional hemodialysis machine can effectively eliminate uremic toxins,maintain electrolyte and acid-base balance,and can accurately display the monitoring parameters.

The Research Progression of Calcitonin for the Therapy of Renal Osteodystrophy

Calcitonin is a common medicine used in the treatment of osteoporosis,which could restrain the activity of osteoclasts,stop the loss of osteocalcin and reduce the transfer of osteocalcin.Calcitonin can also be used in the treatment of the pain-caused diseases which usually cause by hypercalcemia and others such like Paget's disease and bone tumors.As is approved by several clinic researches,calcitonin is powerful in adjusting the level of calcium,phosphorus and PTH during the treatment of renal osteodystrophy.In addition,it could improves the life quality of the patients who suffered from chronic kidney disease(CKD)and extending their life period.At present,several studies have shown us Calcitonin could be treated in renal osteodystrophy.However,the treatment experiences of Calcitonin are still lacking.Better understanding of the clinical evaluation for calcitonin in the treatment of renal osteodystrophy will hopefully help us to improve outcomes for these patients.

The Pathogenesis of the Mechanism of FGF23 in Chronic Kidney Disease Patients with Vascular Calcification

Fibroblast growth factor 23(FGF23)is a protein synthesized by bone cell and the osteoblast with endocrine function.The main role of FGF23 is to regulate serum phosphorus and 1,25(OH)2 D3 levels,it also plays an important role in calcium and phosphorus metabolism.The role of FGF23 in renal disease is to inhibit of phosphorus reabsorption,promote urinary phosphorus excretion and maintain a stable blood phosphorus level.Patients with chronic kidney disease(CKD)have more risk to suffer cardiovascular disease(CVD)which is related to the abnormal metabolism of calcium and phosphorus.FGF23,as newly discovered cardiovascular risk marker,several studies have shown that FGF23 level associates with multiple cardiovascular risk factors in CKD patients,especially in CKD patients with vascular calcification.To explore its pathogenesis of vascular calcification in CKD patients is particularly important,and that may help to take appropriate measures to improve the prognosis of CKD patients.

Application Status and Prospect of Bio-artificial Liver

Liver failure which can be caused by viral hepatitis,alcohol,drugs,metabolic diseases,autoimmune processes or other fac tors is the end stage of chronic liver disease.Although liver transplantation is currently considered to be the primary treatment measures of chronic liver disease.Due to donor shortages,surgical complications and immune rejection,cell therapy has been extensively studied.?Hepa tocyte transplantation and artificial liver have evolved into a simpler alternative to liver failure treatment.Artificial liver can be used as Liver replacement therapy in patients who were waiting for the liver transplantation with chronic liver disease.The ideal biological artificial liver must have the liver material metabolism,detoxification,synthesis and secretion and other functions.Nowadays bio-artificial liver has carried out a large number of clinical trials and get some progress.?This article is now discuss the status of bio-artificial liver and its re placement therapy prospects.

Advances in Diagnosis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus

1 Introduction Neuropsychiatric systemic lupus erythematosus(NPSLE)is a serious complication of systemic lupus erythematosus(SLE),with an incidence of about 30%to 40%[1].No matter early or late SLE patients are prone to concurrent,so early diagnosis and treatment of NPSLE is extremely important.

Peritoneal Dialysis: Prospects and Challenges

There are 3 kinds of Renal Replacement Therapy:hemodialysis,peritoneal dialysis and kidney transplantation.Although a kidney transplant would be the best solution,organ donations are limited and the transplanted organs can be rejected by the body.Hemodialysis is a widely recognized and near-universally available treatment method,however,the patient must make at least 3 weekly visits to a hospital to undergo treatment,with each session lasting on average around 4 hours.Consequently this can have an impact on the patients’life,including work and travel.Since the clinical populariza-

High Performance Soft Electrochemical Actuators Based on Hierarchical Conductive Polymer Ionogels

Electrochemical actuators based on conductive polymers are emerging as a strong competitive in the field of soft actuators because of their intrinsically conformable/elastic nature,low cost,low operating voltage and air-working ability.Recent development has shown that adding electroactive materials,such as CNT and graphene,can improve their actuation performance.Despite the complex material systems used,their output strains(one of the key factors)are generally lower than 1%,which limited further applications of them in multiple scenarios.Here,we report soft electrochemical actuators based on conductive polymer ionogels by embedding polyaniline particles between the PEDOT:PSS nanosheets.Results show that such a hierarchical structure not only leads to a high conductivity(1250 S/cm)but also improved electrochemical activities.At a low operating voltage of 1 V,the maximum strain of these soft actuators reaches an exceptional value of 1.5%,with a high blocking force of 1.3 mN.Using these high-performance electrochemical actuators,we demonstrate soft grippers for manipulating object and a bionic flower stimulated by an electrical signal.This work sets an important step towards enabling the enhanced performance of electrochemical actuators based on conductive polymers with designed microstructures.

Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells

Myeloid-derived suppressor cells(MDSCs)were found to gradually accumulate in the orthotopic esophageal cancer mouse model during tumor progression.Although the roles of MDSCs in promoting tumor growth and inhibiting immune response have been extensively explored,currently,there are still no effective means for targeting MDSCs clinically.The deficiency of specific markers of MDSCs was responsible for the limited strategy to eliminating in clinic.This study identified that GPR84 was exclusively overexpressed on MDSCs.It was further found that GPR84 was prominently expressed on MDSCs in clinical samples and tumor mouse models,which drives the immunosuppression on CD8^(+)T cells by inhibiting PD-L1 degradation in lysosomes.Furthermore,G-CSF and GM-CSF were found to induce GPR84 expression through the STAT3/C/EBPβsignaling pathway.In addition,GPR84+MDSCs and PD-L1^(+)MDSCs were highly accumulated in anti-PD-1 therapy-resistant patients with esophageal cancer,and high GPR84 signature risk was verified as a negative factor for the overall survival of patients with anti-PD-1 treatment.Finally,GPR84 antagonism combined with an anti-PD-1 antibody enhanced the antitumor responses.Therefore,targeting GPR84 enhanced anti-PD-1 efficacy in esophageal cancer and other malignant tumors.This combination therapy has the potential for tumor therapy in clinics.

Biosorption of cesium(Ⅰ) from aqueous solution by a novel exopolymers secreted from Pseudomonas fluorescens C-2: Equilibrium and kinetic studies

The biosorption characteristics of Cs（I） ions from aqueous solution using exopolymers （PFC02） produced from Pseudomonas fluorescens C-2 were investigated as a function of pH, biosorbent dosage, contact time and initial concentration. pH played a major role in the adsorption process, and the optimum pH for the removal of Cs（I） was 8.0. Langmuir, Freundlich and Dubinin-Radushkevich （D-R） models were applied to describe the biosorption isotherm of the Cs（I） ions by PFC02. The Lagergren first-order, pseudo second-order kinetic and intraparticle diffusion models were used to test the kinetic data. Langmuir model and D-R model fitted the equilibrium data better than the Freundlich isotherm. The monolayer adsorption capacities of PFC02 as obtained from Langmuir isotherm at 25°C was found to be 32.63 mg/g. From the D-R isotherm model, the mean free energy was calculated as 26.73 kJ/mol, indicating that the biosorption of cesium was chemisorption. The biosorption process was rapid, and the kinetic rates were best fitted to the pseudo second-order model, which indicated the biosorption process operated through chemisorption mechanism. FT-IR analysis of PFC02 showed the possible functional groups responsible for cesium adsorption were hydroxyl, carboxyl, carbonyl and sulphonate groups. SEM analysis showed the porous structure of the material while EDX analysis confirmed the adsorption of Cs（I） on PFC02. Cesium adsorbed onto the PFC02 could be desorbed efficiently using 1 mol/L HNO 3 , and the enrichment factor was 50.0. Furthermore, PFC02 could be reused five times with only about 8.25% regeneration loss. The developed method was successfully utilized for the removal of Cs（I） ions from aqueous solution.